ALLMedicine™ Blastic Plasmacytoid Dendritic Cell Center
Research & Reviews 191 results
Nature Communications; Cai T, Gouble A et. al.
Apr 29th, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123). Given that CD123 is differentially ...
Blood Advances; Rethnam M, Tan DQ et. al.
Apr 29th, 2022 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with poor clinical outcomes. Dysregulated MYC expression, which is associated with protein arginine methyltransferase 5 (PRMT5) dependency, is a r...
Haematologica Vangala DB, Nilius-Eliliwi V et. al.
Apr 8th, 2022 - Not available.
Blood Yu YT, Chang KC
Apr 8th, 2022 - Immunoblastoid blastic plasmacytoid dendritic cell neoplasm with MYC rearrangement.|2022|Yu YT,Chang KC,|genetics,
https://doi.org/10.1038/s41375-022-01538-9 10.1038/s41590-018-0136-9 10.1182/blood.V97.10.3210 10.1016/j.bbmt.2016.03.022 10.3390/cancers11050595 10.1038/leu.2014.64 10.1097/PAS.0b013e3181c5e26b 10.3324/haematol.2012.072645 10.1186/s13039-016-0232-1 10.1182/blood.V99.11.4154 10.1002/ajh.23567 10.18632/oncotarget.2223 10.1038/leu.2013.283 10.1111/bjh.14146 10.1038/s41375-021-01228-y 10.1038/leu.2017.38 10.1038/s41408-018-0120-5 10.3324/haematol.2020.247569 10.1097/PAS.0000000000001316 10.1111/bjh.17347 10.3324/haematol.2013.093765 10.1038/s41467-020-19119-8 10.1038/gim.2015.30 10.1038/s41375-018-0150-9 10.1056/NEJMoa1408617 10.1038/s41586-020-2819-2 10.1182/blood-2016-05-714030 10.1200/JCO.2012.47.3314 10.1080/10428194.2021.1924372 10.1038/leu.2015.337 10.1182/blood-2015-03-631747 10.1007/s12185-020-03070-x 10.1056/NEJMoa1815105
Leukemia Khanlari M, Yin CC et. al.
Mar 14th, 2022 - Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are reported in up to 20% patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), where a shared clonal origin is shown in individual case studies. In this study...
Drugs 2 results see all →
Clinicaltrials.gov 2 results
Oct 14th, 2020 - Study Design: This is a single center Phase 2 study of myeloablative (MA) and nonmyeloablative (NMA) conditioning, transplantation of partially HLA-mismatched bone marrow or peripheral blood stem cells and post-transplantation cyclophosphamide (Cy...
Aug 9th, 2016 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis. It predominantly affects elderly males with an average age of 67 years at diagnosis and the affected orga...
News 34 results
Yahya Daneshbod, MD, Michael Greas, MD et. al.
Mar 8th, 2022 - The Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm A diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) was rendered. Subsequent needle core biopsy of a left axillary lymph node as well as bone marrow aspiration and biopsy.
Feb 3rd, 2022 - Despite the rarity of patients diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), 2 studies examining treatment options for the disease produced encouraging results and safety data, according to Naveen Pemmaraju, MD. Pemmaraju p...
Oct 6th, 2021 - Naveen Pemmaraju, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase I/II trial of tagraxofusp (SL-401; Elzonris) in patients with intermedia...
Oct 6th, 2021 - Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the trial of SL-401 in blastic plasmacytoid dendritic cell neoplasms (BPDCL). SL-401 is a novel agent under in...
Sep 23rd, 2021 - Dermatologists may be the first clinicians to diagnose blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive hematologic malignancy that involves the skin in about 80% of cases. Courtesy Dr.